Krystal Biotech, Inc. announces preliminary net revenue for 4Q 2025 to be between $106 million to $107 million, with full year net revenue expected to be between $388 million to $389 million. The company has a strong balance sheet and clinical pipeline with multibillion dollar opportunities. Strategic vision includes launching multiple blockbuster medicines in the next four years and treating over 10,000 patients with rare diseases by 2030. The Company also plans to expand its reach in Europe and report top-line results from various clinical trials in 2026. Non-GAAP R&D and SG&A expenses for 2026 are estimated to be between $175 million and $195 million.

For more information, visit Krystal Biotech’s website.

Read more at GlobeNewswire: Krystal Biotech Provides Business Update at 44th Annual